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Abstract
Background: Human male germ cell tumors (GCTs) arise from undifferentiated primordial germ
cells (PGCs), a stage in which extensive methylation reprogramming occurs. GCTs exhibit
pluripotentality and are highly sensitive to cisplatin therapy. The molecular basis of germ cell (GC)
transformation, differentiation, and exquisite treatment response is poorly understood.
Results: To assess the role and mechanism of promoter hypermethylation, we analyzed CpG
islands of 21 gene promoters by methylation-specific PCR in seminomatous (SGCT) and
nonseminomatous (NSGCT) GCTs. We found 60% of the NSGCTs demonstrating methylation in
one or more gene promoters whereas SGCTs showed a near-absence of methylation, therefore
identifying distinct methylation patterns in the two major histologies of GCT. DNA repair genes
MGMT,  RASSF1A, and BRCA1, and a transcriptional repressor gene HIC1, were frequently
methylated in the NSGCTs. The promoter hypermethylation was associated with gene silencing in
most methylated genes, and reactivation of gene expression occured upon treatment with 5-Aza-
2' deoxycytidine in GCT cell lines.
Conclusions: Our results, therefore, suggest a potential role for epigenetic modification of critical
tumor suppressor genes in pathways relevant to GC transformation, differentiation, and treatment
response.
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Background
Promoter methylation has been well recognized as an im-
portant epigenetic change in the development of cancer
[1]. Normally, CpG islands in the promoter regions of a
number of genes are present in an unmethylated state [2].
Aberrant methylation of CpG islands in promoters is char-
acteristic of several genes in cancer leading to loss of gene
expression. A nonrandom pattern of promoter hyper-
methylation has been noted in specific genes in specific
tumor types, although some genes are commonly methyl-
ated in diverse tumors [3,4]. The extent of aberrant pro-
moter hypermethylation and its association with loss of
gene function in cancer suggests that CpG island methyl-
ation is an important mechanism in inactivating tumor
suppressor genes (TSGs).
Germ cell tumors (GCTs) are the most common cancer in
men between the ages 20–40 with an incidence of 4.2 cas-
es per 100,000 [5]. GCTs arise by transformation of sper-
matogonial lineage cells and display pluripotentiality for
embryonal and extra-embryonal lineage differentiation
[6]. Histologically, they may present as undifferentiated
germ cell (GC)-like seminomas (SGCTs) or highly differ-
entiated nonseminomas (NSGCTs). NSGCTs display
complex differentiation patterns that include embryonal,
extra-embryonal, and somatic tissue types [6]. Teratomas
with somatic differentiation can undergo additional ma-
lignant transformation with characteristics of epithelial,
mesenchymal, neurogenic, or hematologic tumors [7].
While the majority of GCTs exhibit exquisite sensitivity to
cisplatin-based chemotherapy, a small proportion of met-
astatic tumors remain resistant. Therefore, male GCTs
comprise a unique model system to investigate the biolo-
gy and genetics of GC transformation, differentiation, and
chemotherapy resistance/sensitivity [6].
During the life span of a normal GC, extensive methyla-
tion reprogramming occurs [6]. However, the role of epi-
genetic changes in GCT etiology and biology are not well
studied. To investigate such a role, we evaluated the status
of promoter hypermethylation of 21 genes in GCT speci-
mens and cell lines. We found an absence of promoter hy-
permethylation in SGCT and acquisition of unique
patterns of promoter hypermethylation in NSGCT. We
also showed that the hypermethylation leads to loss of ex-
pression in most of the genes and reactivate upon treat-
ment with demethylating drug 5-Aza-2' deoxycytidine.
Results
Promoter hypermethylation is common in NSGCT and 
rare in SGCT
We assessed 92 GCT DNAs representing all histologic sub-
sets of NSGCT, and SGCT, and four normal testes for
methylation status of CpG islands of 21 gene promoters
by methylation-specific PCR (MSP) (Fig. 1). Of these, 15
genes (MGMT,  RASSF1A,  APC,  RARB,  CDH1,  MLH1,
TIMP3, GSTP1, DAPK, CDKN2A, p14ARF, BRCA1, FHIT,
TP73, and HIC1) had previously been shown to be com-
monly methylated in various solid tumor types [4]. Six ad-
ditional genes (RB1, NME1, NME2, BTG1, NEDD1, and
APAF1) were studied because of their possible involve-
ment in genetic alterations in GCT as indicated by LOH
studies [8–10]. The RB1 gene at 13q14.2 showed frequent
loss of heterozygosity (LOH) in GCT [9]. The NME1 and
NME2 genes mapped to 17q21.3 also were affected by
LOH and exhibited loss of expression in teratoma [9]. The
BTG1, APAF1, and NEDD1 genes mapped to the 12q22
common-deletion region, and thus considered as candi-
date TSGs in GCT [8,10,11].
Promoter hypermethylation was not found in normal tes-
tes for any of the tested genes except CDH1. CDH1 exhib-
ited methylation in two of the four normal testes
analyzed. However, promoter hypermethylation was de-
tected in 43 of the 92 (46.7%) GCTs studied with an indi-
vidual gene frequency of: RASSF1A, 21.7%; MGMT,
20.7%; BRCA1, 19.8%, HIC1, 19.6%; APC, 9.8%; RARB,
7.6%; CDH1, 7.6%; FHIT, 6.5%, MLH1, 4.3%; TIMP3,
3.3%; GSTP1, 1.1%; and NME2, 1.1% (Fig. 1). The re-
maining nine genes did not show methylation. Hyper-
methylation of one or more genes was found only in 5 of
29 (17.2%) SGCTs but in 38 of 63 (60.3%) NSGCTs (Fig.
1). Four of the five SGCTs that exhibited promoter hyper-
methylation were methylated at a single locus and one tu-
mor at two loci, whereas 27 of the 38 NSGCTs exhibited
two or more methylated loci. Promoter hypermethylation
was seen in all histologic subsets of NSGCT, with yolk sac
tumor (YST) exhibiting a higher frequency of methylation
compared to other histologies (Fig. 2 & Fig. 3).
Relationship between promoter hypermethylation and 
gene expression
To examine the biological role of promoter hypermethyl-
ation in GCT, we assessed the levels of gene expression by
semi-quantitative RT-PCR in 23 tumors (15 NSGCTs and
8 SGCTs) with known methylation status. Eight genes
(MGMT, RASSF1A, BRCA1, APC, RARB, CDH1, MLH1,
and TIMP3) that exhibited methylation in >3% of the cas-
es were examined (Fig. 4, Table 1). Levels of expression of
each gene were assessed by comparing with the respective
control values, obtained from the averages calculated
from 2 to 4 normal testes, after normalization against
ACTB. All tumors with promoter hypermethylation of the
MGMT and MLH1 genes exhibited an absence or down-
regulated expression of the respective gene, while 8 of 10
cases with RASSF1A methylation and 3 of 5 tumors with
RARB methylation showed down-regulated expression
(Table 1). The other four genes (BRCA1, APC, CDH1, and
TIMP3) did not show a consistent pattern of correlation
between methylation and loss of gene expression (TableMolecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/8
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1). Of note, the MGMT gene exhibited down-regulated ex-
pression in 22 of the 23 (95.7%) tumors, including all the
tumors that showed promoter methylation. No consistent
down-regulation of expression of the other genes that
lacked promoter methylation was detected in the same
panel of specimens. These data, thus, showed loss of
MGMT expression in majority of GCTs of all histologic
subsets.
Demethylation reactivates the gene expression
To further examine the role of promoter methylation in
gene inactivation, we treated five NSGCT cell lines
(2102E-R, 833K-E, Tera-1, Tera-2, and 218A) with 5-Aza-
2' deoxycytidine and analyzed the expression of MGMT,
RASSF1A, RARB, and BRCA1 genes. The MGMT gene ex-
hibited promoter hypermethylation in four of the cell
lines, which upon treatment with 5-Aza-2' deoxycytidine
showed reactivation of expression in three (2102E-R,
833K-E, and Tera-2). The cell line Tera-1 did not reactivate
expression after azacytidine treatment (Fig. 5). One cell
line (T-218A) showed no promoter hypermethylation of
MGMT by MSP and no detectable levels of mRNA expres-
sion by RT-PCR but expression was reactivated after 5-
Aza-2' deoxycytidine treatment. Two of the five cell lines
showed methylation in the RARB gene, one of which
(Tera-2) showed detectable levels of gene expression in
untreated cells (Fig. 5). The other four cell lines including
the one with promoter hypermethylation (2102E-R) ex-
hibited no detectable levels of RARB expression. Azacyti-
dine treatment activated gene expression in all the five cell
lines, whether or not promoter had detectable methyla-
tion (Fig. 5). The RASSF1A gene was methylated in 3 of
the 5 cell lines studied. While one of the methylated cell
lines showed expression in untreated cells, all other cell
lines did not show detectable levels of mRNA. Azacytidine
treatment reactivated expression of RASSF1A in one of
each of the two methylated and two unmethylated cell
lines. The BRCA1 gene showed promoter methylation in
Figure 1
Analysis of promoter methylation in GCT. Frequency of CpG methylation in nonseminomatous and seminomatous his-
tologies.
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2 of 5 cell lines. Irrespective of whether the promoter is
methylated or not, the BRCA1 gene was expressed in all
cell lines and the treatment of azacytidine had little or no
effect on levels of gene expression (Fig. 5)
Discussion
Epigenetic mechanisms of gene silencing are increasingly
being recognized to affect a number of molecular path-
ways in human cancer [12]. The extent and the nature of
such epigenetic modifications in GCTs are currently poor-
ly understood. Here we show that hypermethylation is
common in NSGCT and rare in SGCT. Several studies
have shown that both NSGCTs and SGCTs exhibit similar
genetic alterations, including isochromosome for the
short arm of chromosome 12, i(12p) [6]. Thus epigenetic
alterations such as those detected in the current study is
one distinct molecular change that distinguishes these
two histologic subsets. The rare CpG hypermethylation
seen in five SGCT patients may be due to the existence of
a minor NSGCT component that might have escaped the
histologic diagnosis. A unique feature of GCTs is their or-
igin from germ cells at a stage in development where they
undergo epigenetic reprogramming [6,13]. The absence of
this epigenetic modification in SGCTs is consistent with
their GC-like nature as previously noted [6,14]. On the
other hand, the extensive promoter hypermethylation
seen in NSGCTs suggests a mechanistic role in their poten-
tial for embryonal and extra-embryonal lineage differenti-
ation [6,14]. Establishment of DNA methylation in the
mammalian genome is controlled by at least three DNA
methyltransferases (DNMTs), DNMT1,  DNMT3a  and
DNMT3b [15]. The role of these DNMTs in differential de
novo methylation in SGCT vs. NSGCT remains to be elu-
cidated.
The overall higher frequency of promoter methylation
seen in NSGCTs is noticeably evident in DNA repair genes
RASSF1A, BRCA1, and MGMT, and the hypermethylated
in cancer 1 (HIC1) gene, which encodes a transcription
factor. These genes map to sites already known to be ge-
netically altered in GCT specimens. The 3p21.3 region to
Figure 2
Frequency of CpG methylation in different histologic subsets of nonseminoma.
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Figure 3
Methylation-specific PCR of MGMT gene. U, unmethylated;
M, methylated; Tumor (T) and cell line (CL) numbers are
indicated on the top.Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/8
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which RASSF1A maps undergoes deletions in many solid
tumor types, including GCTs [9]. RASSF1A  encodes a
splice variant of human RAS effector homologue, which
interacts with the XPA protein and functions as a negative
regulator of cell growth [16,17]. RASSF1A has been shown
to be inactivated by promoter methylation in a variety of
tumor types [16–19]. The 17q21 and 17p13 regions, to
which BRCA1 and HIC1 map, respectively, also have been
characterized by high frequency of LOH in GCT [9]. The
BRCA1 gene plays critical roles in DNA repair and recom-
bination, cell cycle checkpoint control, and transcription
and has been shown to be hypermethylated in breast-
ovarian cancer [4]. The HIC1 gene is also often hyper-
methylated in many human cancers [20–22]. The DNA re-
pair gene MGMT  encodes O(6)-methylguanine-DNA
methyltransferase and this enzyme effectively removes
DNA adducts formed by alkylating agents [23]. Epigenetic
inactivation of the MGMT gene was reported in a wide va-
riety of cancers [24,25]. Also, a low frequency of methyla-
tion of the APC, RARB, and FHIT genes was detected in
NSGCTs. Thus, the frequent hypermethylation in the MG-
MT, BRCA1, and RASSF1A, and HIC1 define the methyla-
tion profile in NSGCT. These data suggest that promoter
hypermethylation leading to gene silencing may affect key
pathways in germ cell tumorigenesis.
Aberrant promoter methylation changes that occur in can-
cer are associated with transcriptional repression and loss
of function of the gene by interrupting the binding of pro-
teins involved in transcription activator complex [12].
Our gene expression analysis by RT-PCR demonstrated
that all tumors that showed methylation of MGMT and
MLH1  also showed down-regulated expression, while
RASSF1A  and  RARB  genes showed down-regulation of
mRNA levels in most of the methylated tumors. Thus in
these cases, promoter hypermethylation is one mecha-
Table 1: Relation between promoter hypermethylation by MSP and gene expression by RT-PCR.
Gene No. Studied 
(% down-regulated)
Methylation status and expression levels
Methylated Unmethylated
No. Lack of or down-regu-
lated expression (%)
No. Lack of or down-regu-
lated expression (%)
MGMT 23 (95.7) 8 8 (100) 15 14 (93.3)
RASSF1A 22 (50.0) 10 8 (80) 12 3 (25)
RARB 22 (40.9) 5 3 (60) 17 6 (35.3)
MLH1 21 (33.3) 3 3 (100) 18 4 (22.2)
BRCA1 16 (18.8) 6 2 (33.3) 10 1 (10)
APC 23 (26.1) 2 - (0) 21 6 (28.6)
CDH1 20 (20.0) 2 1 (50) 18 3 (16.7)
TIMP3 20 (15.0) 3 1 (33.3) 17 2 (11.8)
Figure 4
Analysis of gene expression of MGMT gene in GCT. Multiplex RT-PCR analysis. Tumor (T) and cell line (CL) numbers
are indicated on the top. Actin was used as an internal control.Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/8
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nism whereby gene expression can be deregulated in
GCTs. On the other hand, methylation of BRCA1, APC,
CDH1, and TIMP3 genes did not correlate with expression
levels. Interestingly, MGMT gene was also down regulated
in 14 of the 15 tumors that did not exhibit methylation by
MSP analysis. Therefore, these data indicate that other ep-
igenetic and/or genetic changes may be involved in regu-
lating the expression of MGMT in GCT. The MSP method
detects only methylation of full-length CpG islands and
cannot identify partial methylation of the promoters.
Thus, role of partial methylation in down-regulating
MGMT cannot be ruled out. Other epigenetic mechanisms
involving defects in chromatin modification factors such
as the association of methyl-CpG binding proteins,
acetylation and methylation of histone proteins are also
becoming known [15]. The role of these chromatin-medi-
ated components in inactivating the MGMT gene remains
to be examined in GCT. To determine whether the down-
regulated expression of the MGMT gene is due to genetic
mutations, we examined the entire coding region in 30
GCTs and found no inactivating mutations (unpublished
observations).
Epigenetic gene silencing of the MGMT confers enhanced
sensitivity to alkylating agents in cancer [24,25]. Lack of
methylation, on the other hand, associates with high-risk
of death [25,26]. It has been suggested that the high-levels
of MGMT proteins contribute to a drug-resistant pheno-
type [27]. More than 90% of newly diagnosed GCTs and
70–80% of patients who present metastatic disease are
cured with cisplatin-based chemotherapy [28]. However,
20–30% of the patients with metastatic disease exhibit re-
sistance to the cisplatin curative regimen leading to high
mortality in this group. The molecular basis of this exqui-
site chemotherapy sensitivity of GCT and resistance is
poorly understood. We have previously shown that sub-
sets of resistant tumors exhibit TP53 gene mutations and
chromosomal amplifications [6]. However, the role of
MGMT in GCT sensitivity or resistance to chemotherapy is
not known. Our current observation that undetectable
levels of MGMT gene expression in >95% of GCTs appears
to suggest that the lack of the O(6)-methylguanine-DNA
methyltransferase enzyme may direct cells to undergo ap-
optosis due to failure of repair of DNA adducts formed by
alkylating agents. Lack of MGMT expression in the major-
ity of GCTs suggests a potential role for this protein in lack
of repair of cisplatin-induced DNA damage that may re-
sult in exquisite sensitivity in this tumor. It has been
shown that engineered over-expression of wild-type p53
in vitro causes inhibition of MGMT transcription in hu-
man tumor cells [29]. Abundant over-expression of wild-
type p53, owing to their stage of origin, is a characteristic
feature of GCTs [30]. A possibility also exists that the
MGMT expression may, in general, be down regulated in
tumors arising from embryonic-type cells. To examine
this, we analyzed 22 cases of Wilms' tumor but found no
decreased levels of the MGMT gene expression (data not
shown). These data, therefore, rule out the possibility that
not all tumors arising from embryonic-type cells show
down-regulated expression of MGMT.
Transcriptional silencing of genes resulting from DNA hy-
permethylation of CpG islands is reversed by treatment of
the hypo-methylating agent 5-aza-2'-deoxycytidine in a
dose and duration-dependent manner. Since a number of
gene promoters were hypermethylated and showed
down-regulated mRNA in GCT, we wanted to test whether
hypomethylation reactivates the gene expression in these
tumors. We found that azacytidine treatment resulted in
reactivation of gene expression in almost all cell lines that
showed promoter methylation of MGMT, RASSF1A and
RARB genes, with the exception of the cell line Tera-1. In
addition, a number of genes that showed no evidence of
full-length CpG methylation was also reactivated upon
azacytidine treatment. This was most evident for the RARB
gene, where all five cell lines showed reactivation whether
or not the promoter was methylated. These data thus sug-
gest that global demethylation may not only influence the
expression of methylated genes but also unmethylated
genes. Such a phenomenon has previously been reported
[31,32].
Conclusions
The data presented here show that promoter hypermeth-
ylation is an important molecular signature differentiat-
Figure 5
Analysis of gene expression after treatment of GCT cell lines
with the demethylating drug 5-Aza-2' deoxycytidine. Un,
untreated; Tr, treated with Azacytidine. Actin was used as an
internal control. Cell lines are indicated on the top.Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/8
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ing seminomatous and nonseminomatous GCTs.
Promoter methylation was frequently seen in DNA repair
genes MGMT, RASSF1A, and BRCA1, and a transcriptional
repressor gene HIC1. Promoter methylation of most genes
resulted in transcriptional repression. The data also sug-
gest that multiple mechanisms, in addition to the promot-
er methylation, may play a role in silencing of MGMT
gene expression in GCTs of all histologic subsets. Given
the importance of the MGMT protein in treatment re-
sponse to alkylating agents, this molecular switch may
play a critical role in sensitivity to cisplatin-based therapy
in GCTs. Demethylation of the promoters reactivated the
gene expression in MGMT,  RARB  and RASSF1A  genes.
Further characterization of the exact mechanisms in-
volved in epigenetic gene silencing, especially in the
MGMT gene, may provide important clues in understand-
ing the pathways relevant to GCT biology.
Methods
Tumor tissues and cell lines
A total of 92 GCT tumor tissues consisting of 83 primary
tumors and nine cell lines were used in this study. The tu-
mor biopsies were ascertained from patients evaluated at
Memorial Sloan-Kettering Cancer Center (MSKCC) as de-
scribed previously [11] after appropriate institutional re-
view board approval. Frozen tumor tissues or cell pellets
were utilized for DNA and/or RNA isolation by standard
methods. Histologically, 29 of these tumors were SGCTs,
44 NSGCTs, and 19 mixed or combined tumors. Nine cell
lines derived from GCT have been previously described
[8]. DNA and RNA isolated from four normal testes were
used as controls.
Methylation Specific PCR (MSP)
Genomic DNA was treated with sodium bisulphite as pre-
viously described [33]. Placental DNA treated in vitro
with SssI methyltransferase (New England Biolabs, Bever-
ly, MA) and similarly treated normal lymphocyte DNA
were used as controls for methylated and unmethylated
templates, respectively. The primers used for methylated
and unmethylated-specific PCR for genes RARB, TIMP3,
CDKN2A,  p14ARF,  MGMT,  DAPK,  CDH1,  GSTP1,  APC
promoter 1A, RB1, MLH1, TP73, BRCA1, FHIT, and HIC1
have been described previously  [http://
pathology2.jhu.edu/pancreas/prim0425.htm#MSP]; [34–
37]. For additional genes, we designed the following gene-
specific primers for methylated (MF and MR) and un-
methylated (UF and UR) sequences according to Herman
et al [33]:
BTG1-MF 5'-GTCGTTCGTTTTTTACGTTTTT-3'
BTG1-MR 5'-CGACCCGAATATAAAAAAAATAC-3'
BTG1-UF 5'-GTTGTTTGTTTTTTATGTTTTTTTT-3'
BTG1-UR 5'-CAACCCAAATATAAAAAAAATACA-3'
NEDD1-MF 5'-GGATATTTTTTAGTTTAGCGCG-3'
NEDD1-MR 5'-CGACCCCCTATTATATTACTACG-3'
NEDD1-UF 5'-TGGATATTTTTTAGTTTAGTGTG-3'
NEDD1-UR 5'-CAACCCCCTATTATATTACTACA-3'
APAF1-MF 5'-GCGCGTTCGTTTATGTAAATA-3'
APAF1-MR 5'-CAAACCGACGAAACCCGAA-3'
APAF1-UF 5'-GGTGTGTGTTTGTTTATGTAAATA-3'
APAF1-UR 5'-CACAAACCAACAAAACCCAAA-3'
NME1-MF 5'-GTTTCGTGCGTGTAAGTGTTG-3'
NME1-MR 5'-CCACCGACAAAAACGAATCCA-3'
NME1-UF 5'-GTTTTGTGTGTGTAAGTGTTGT-3'
NME1-UR 5'-CCACCAACAAAAACAAATCCAC-3'
NME2-MF 5'-TTTTCGGTCGCGTCGGGTC-3'
NME2-MR 5'-GCGCGAAACCTACGAAAAATC-3'
NME2-UF 5'-GTTTTTTGGTTGTGTTGGGTTG-3'
NME2-UR 5'-CACACAAAACCTACAAAAAATCA-3'
RASSF1A-MF 5'-ACGCGTTGCGTATCGCGCG-3'
RASSF1A-MR 5'-CCGCGACGACTACGCTACC-3'
RASSF1A-UF 5'-ATGTGTTGTGTATTGTGTGGGG-3'
RASSF1A-UR 5'-CCACAACAACTACACTACCCC-3'
PCR products were run on 2% agarose gels and visualized
after ethidium bromide staining. Purified MSP products
were sequenced in representative specimens by direct se-
quencing to confirm the methylation scored on agarose
gels.
Semi-quantitative analysis of mRNA expression
To assess gene expression, total RNA isolated from normal
testes, the cell lines, and tumor tissues, and polyA+ RNA
of testis obtained from Clontech (Palo Alto, CA) was re-
verse transcribed using random primers and the Pro-STAR
first strand RT-PCR kit (Stratagene, La Jolla, CA). A semi-
quantitative analysis of gene expression was performedMolecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/8
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using 26 to 28 cycles of multiplex RT-PCR with β-actin
(ACTB) as control and gene specific primers spanning at
least 2 exons, except in RASSF1A. For the latter, we used
single PCR with primers and conditions as previously de-
scribed [16]. The gene primers used and their positions in
respective cDNAs were:
MGMT-F 5'-GCACGAAATAAAGCTCCTGG-3' (124–143
bp)
MGMT-R 5'-AGGGCTGCTAATTGCTGGTA-3' (380–399
bp)
MLH1-F 5'-CTGGACGAGACAGTGGTGAA-3' (52–71 bp)
MLH1-R 5'-CTCACCTCGAAAGCCATAGG-3' (308–327
bp)
APC-F 5'-AAGCCGGGAAGGATCTGTAT-3' (329–348 bp)
APC-R 5'-TCCAATTGCCTTCTGGTCAT-3' (588–607 bp)
RARB-F 5'-AATTCAGTGAACTGGCCACC-3' (770–789
bp)
RARB-R 5'-GGCAAAGGTGAACACAAGGT-3' (1010–1029
bp)
CDH1-F 5'-CTCGACACCCGATTCAAAGT-3' (335–354
bp)
CDH1-R 5'-TGGGCCTTTTTCATTTTCTG-3' (615–634 bp)
TIMP3-F 5'-CTTCCGAGAGTCTCTGTGGC-3' (1440–1450
bp)
TIMP3-R 5'-GGCGTAGTGTTTGGACTGGT-3' (1713–
1732 bp)
BRCA1-F 5'-TCAGCTTGACACAGGTTTGG-3' (676–695
bp)
BRCA1-R 5'-GGTTGTATCCGCTGCTTTGT-3' (896–915
bp)
The PCR products were run on 1.5% agarose gels, visual-
ized by ethidium bromide staining and quantitated using
the Kodak Digital Image Analysis System (Kodak, New
Haven, CT). A tumor was considered to have lost expres-
sion when the gene showed complete lack of expression
or at least 50% reduction from the normalized values ob-
tained from the average calculated utilizing 2 to 4 normal
testes. The effect of methylation on gene expression was
similarly assessed on total RNA isolated from cell lines
treated with the demethylating agent 5-Aza-2' deoxycyti-
dine (Sigma) for five days at a concentration of 2–5 µM.
Analysis of mutations
Single strand conformational polymorphism (SSCP)
analysis was performed on all coding exons using primers
flanking intronic sequences of the MGMT gene by stand-
ard methods.
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